Determinants of the extent and duration of STAT3 signaling

Figures & data

Table 1. Molecular alterations resulting in the enhanced activation of STAT3 „signaling

Components and mechanisms	Cells and phenotypes	References
v-src, activated oncogenic version of the tyrosine kinase c-src	Fibroblast transformation	8 and 9
JAK2 (V617F), activating mutation in the tyrosine kinase domain	Myeloproliferative neoplasms	10, 11 and 12
gp 130, activating deletion of the ligand binding site in the IL-6 coreceptor	Inflammatory hepatocellular adenoma	13
STAT3 (Y640F and D661V), activating mutations in the dimerization domain	Hepatocellular adenoma, T cell large granular lymphocytic leukemia	14 and 15
G-CSF receptor activation through increased JAK2 expression	Hematopoietic cell transformation	16
Sphingosine 1 phosphate receptor overexpression, auxilliary in IL-6 dependent STAT3 activation	B16 mouse melanoma cells, human breast cancer	17
EGF receptor, mutation in the kinase domain, induces IL-6 secretion	Human lung adenocarcinomas	20
Ras, oncogenic mutation induces IL-6 secretion	Pancreatic cancer	19
IL-6, autoregulation, autocrine induction of IL-6 secretion	Lung adenocarcinoma cells	22

Table 2. Molecular alterations resulting in the diminished deactivation of „STAT3

Components and mechanisms	Cells and phenotypes	References
PTP, protein tyrosine phosphatases, transcriptional silencing, deletion mutations	Glioblastoma multiforme, head and neck squamous cell carcinoma, lung cancer	2
SOCS, suppressors of cytokine signaling, promoter methylation and transcriptional silencing	Lung and breast cancer, mesotheliomas	26
SOCS-1, PMT-induced expression of Pim-1, inhibition of SOCS-mediated E3 ubiquitin ligase activity	Rat-1 fibroblasts, enhanced cell proliferation	28 and 27
PIAS, protein inhibitors of activated STAT, post-transcriptional silencing	Glioblastoma and breast cancer	6
LNK, lymphocyte adaptor protein, deletion mutations	Myeloproliferative diseases	30

Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269:81 - 3; http://dx.doi.org/10.1126/science.7541555; PMID: 7541555

 PubMed Web of Science ®Google Scholar

Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997; 8:1267 - 76; PMID: 9419415

 PubMedGoogle Scholar

Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol 2010; 3:323 - 37; http://dx.doi.org/10.1586/ehm.10.28; PMID: 21082983

 PubMed Web of Science ®Google Scholar

Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011; 86:668 - 76; http://dx.doi.org/10.1002/ajh.22063; PMID: 21674578

 PubMed Web of Science ®Google Scholar

Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673 - 83; http://dx.doi.org/10.1038/nrc2210; PMID: 17721432

 PubMed Web of Science ®Google Scholar

Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457:200 - 4; http://dx.doi.org/10.1038/nature07475; PMID: 19020503

 PubMed Web of Science ®Google Scholar

Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011; 208:1359 - 66; http://dx.doi.org/10.1084/jem.20110283; PMID: 21690253

 PubMed Web of Science ®Google Scholar

Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366:1905 - 13; http://dx.doi.org/10.1056/NEJMoa1114885; PMID: 22591296

 PubMed Web of Science ®Google Scholar

Meenhuis A, Irandoust M, Wölfler A, Roovers O, Valkhof M, Touw IP. Janus kinases promote cell-surface expression and provoke autonomous signalling from routing-defective G-CSF receptors. Biochem J 2009; 417:737 - 46; http://dx.doi.org/10.1042/BJ20081153; PMID: 18922133

 PubMed Web of Science ®Google Scholar

Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16:1421 - 8; http://dx.doi.org/10.1038/nm.2250; PMID: 21102457

 PubMed Web of Science ®Google Scholar

Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117:3846 - 56; http://dx.doi.org/10.1172/JCI31871; PMID: 18060032

 PubMed Web of Science ®Google Scholar

Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007; 21:1714 - 9; http://dx.doi.org/10.1101/gad.1549407; PMID: 17639077

 PubMed Web of Science ®Google Scholar

Huang WL, Yeh HH, Lin CC, Lai WW, Chang JY, Chang WT, et al. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 2010; 9:309; http://dx.doi.org/10.1186/1476-4598-9-309; PMID: 21122157

 PubMed Web of Science ®Google Scholar

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315

 PubMed Web of Science ®Google Scholar

He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 2003; 100:14133 - 8; http://dx.doi.org/10.1073/pnas.2232790100; PMID: 14617776

 PubMed Web of Science ®Google Scholar

Hildebrand D, Walker P, Dalpke A, Heeg K, Kubatzky KF. Pasteurella multocida Toxin-induced Pim-1 expression disrupts suppressor of cytokine signalling (SOCS)-1 activity. Cell Microbiol 2010; 12:1732 - 45; http://dx.doi.org/10.1111/j.1462-5822.2010.01504.x; PMID: 20633028

 PubMed Web of Science ®Google Scholar

Limnander A, Rothman PB. Abl oncogene bypasses normal regulation of Jak/STAT activation. Cell Cycle 2004; 3:1486 - 8; http://dx.doi.org/10.4161/cc.3.12.1297; PMID: 15611644

 PubMed Web of Science ®Google Scholar

Borghouts C, Tittmann H, Delis N, Kirchenbauer M, Brill B, Groner B. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death. Mol Cancer Res 2010; 8:539 - 53; http://dx.doi.org/10.1158/1541-7786.MCR-09-0417; PMID: 20371673

 PubMed Web of Science ®Google Scholar

Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116:988 - 92; http://dx.doi.org/10.1182/blood-2010-02-270108; PMID: 20404132

 PubMed Web of Science ®Google Scholar